Staudacher Dawid L, Felder Meret, Jäckel Markus, Rottmann Felix A, Supady Alexander, Bemtgen Xavier, Diehl Philipp, Wengenmayer Tobias, Zotzmann Viviane
Interdisciplinary Medical Intensive Care, Faculty of Medicine and Medical Center, University of Freiburg, 79085 Freiburg, Germany.
Department of Cardiology and Angiology, Faculty of Medicine, Heart Center Freiburg University, University of Freiburg, 79085 Freiburg, Germany.
J Clin Med. 2025 Mar 24;14(7):2206. doi: 10.3390/jcm14072206.
: Desirable outcome after venovenous extracorporeal membrane oxygenation for acute respiratory distress syndrome (ARDS) is frequently defined by survival. However, quality of life (QoL) and mental health status may take precedence over mere survival, from a patient-centered perspective. We aimed to evaluate QoL and mental health status in survivors after V-V ECMO for coronavirus disease 2019 (COVID-19)-related ARDS, hypothesizing a similar QoL comparable to the general population. : All patients supported with venovenous ECMO for COVID-19-related ARDS between 01/2020 and 03/2022 in our center were included. Survivors were invited to participate in a follow-up interview assessing QoL, anxiety, and depression one year after hospital discharge. Primary endpoint was the quality of life, measured by the SF-36 questionnaire, with results compared to data from the DEGS1 study (German normative population). : During the study period, 97 patients received venovenous ECMO for COVID-19 ARDS at our ICU. Overall, 43/97 (44.3%) survived, and 21/97 (21.6%) completed the SF-36 questionnaire. The median follow-up duration was 1.7 years. Patients who completed the SF-36 were significantly younger than those who did not (48.7 vs. 55.6 years, = 0.012); other patient characteristics and ECMO parameters were similar between those with and without questionnaire. Anxiety, depression, and post-traumatic stress disorder were detected in 33%, 14%, and 29% of patients, respectively. Compared to the German normative population, ECMO survivors had significantly lower QoL (mean 77.2 vs. 61.0, < 0.001). : QoL and mental health status after venovenous ECMO for ARDS was significantly lower compared to the normative population. These findings highlight the importance of further research and comprehensive follow-up care for ECMO survivors.
对于急性呼吸窘迫综合征（ARDS）患者，静脉 - 静脉体外膜肺氧合（V - V ECMO）治疗后的理想结局通常以生存来定义。然而，从以患者为中心的角度来看，生活质量（QoL）和心理健康状况可能比单纯的生存更为重要。我们旨在评估2019冠状病毒病（COVID - 19）相关ARDS患者接受V - V ECMO治疗后的幸存者的生活质量和心理健康状况，假设其生活质量与普通人群相似。：纳入了2020年1月至2022年3月期间在我们中心接受V - V ECMO治疗的COVID - 19相关ARDS的所有患者。邀请幸存者在出院一年后参加随访访谈，评估生活质量、焦虑和抑郁情况。主要终点是生活质量，通过SF - 36问卷进行测量，并将结果与DEGS1研究（德国标准人群）的数据进行比较。：在研究期间，97例患者在我们的重症监护病房接受了V - V ECMO治疗以治疗COVID - 19 ARDS。总体而言，43/97（44.3%）存活，21/97（21.6%）完成了SF - 36问卷。中位随访时间为1.7年。完成SF - 36问卷的患者明显比未完成的患者年轻（48.7岁对55.6岁，P = 0.012）；完成问卷和未完成问卷的患者在其他患者特征和ECMO参数方面相似。分别有33%、14%和29%的患者被检测出患有焦虑、抑郁和创伤后应激障碍。与德国标准人群相比，ECMO幸存者的生活质量显著更低（平均77.2对61.0，P < 0.001）。：与标准人群相比，ARDS患者接受V - V ECMO治疗后的生活质量和心理健康状况显著更低。这些发现凸显了对ECMO幸存者进行进一步研究和全面随访护理的重要性。
